证券代码：300412 证券简称：迦南科技 浙江迦南科技股份有限公司 投资者关系活动记录表 编号：20191211 | --- | --- | --- | |--------------|------------------------|--------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ | 新闻发布会 □路演活动 | | 动类别 | □ 现场参观 | | | | □其他 | | | 调研单位 | | 杭州萧山农商基金管理有限公司：马伟俊（基金经理）、李志 | | | | 杰（基金经理）、盛江宏（业务副总） | | 时间 | 2019 年 12 月 | 11 日下午 | | 地点 | 公司会议室 | | | 上市公司接待 | 副总经理兼董秘：晁虎 | | | 人员姓名 | 董事办工作人员：李健 | | | 投资者关系活 | 一、公司基本情况介绍； | | | 动主要内容介 | | | | 绍 | 二、互动问答环节： ...

证券代码：300412 证券简称：迦南科技 浙江迦南科技股份有限公司 投资者关系活动记录表 编号：20210521 | --- | --- | |--------------|-----------------------------------------------------------------------------------| | | | | | 特定对象调研 □ 分析师会议 | | | □ 业绩说明会 | | 投资者关系 | 新闻发布会 □ 路演活动 | | | | | 活动类别 | | | | | | 参与单位 | 中庚基金管理有限公司：季国峰（研究员） 上海南土资产管理有限公司：黄文睿（研究员） | | 时间 | 21 日下午 | | 地点 | 公司一楼会议室 | | 上市公司接 | 总经理：方正 | | 待人员姓名 | 副总经理兼董秘：晁虎 证券专员：李健 | | | 一、公司基本情况介绍； | | | 二、互动问答环节 | | 投资者关系 | 年下半年以来行业内的几家公司订单同步好转，背后的 | | 活动主要内 | 原因是什么？ | | 容介绍 | 答：其实整个制药装备市场工业产值一 ...

证券代码：300412 证券简称：迦南科技 浙江迦南科技股份有限公司 投资者关系活动记录表 编号：20210908 | --- | --- | --- | --- | |--------------|-------------------------------------------|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------| | | 特定对象调研 | □ | 分析师会议 | | | □ 媒体采访 | □ | 业绩说明会 | | 投资者关系 | □ 新闻发布会 | □ 路演活动 | | | 活动类别 | □ 现场参观 | | | | | □ 其他 | | | | 参与单位 | 阳（医药行业研究员） | | 光大证券股份有限公司：林小伟（医药行业首席分析师）、彭天 | | 时间 | 2021 年 9 月 8 日 ...

证券代码：300412 证券简称：迦南科技 浙江迦南科技股份有限公司 投资者关系活动记录表 编号：20211216 | --- | --- | --- | |--------------|-------------------------------------------|----------------------------------------------------------------| | | | | | | 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投资者关系 | □ 新闻发布会 | □ 路演活动 | | 活动类别 | □ 现场参观 | | | | □ 其他 | | | | 姓名 | 单位 | | | 秦乾一 | 南方基金管理股份有限公司 | | 参与人员及 | 任逸哲 | 中欧基金管理有限公司 | | 单位 | 马云涛 | 西南证券股份有限公司 | | | 韩盟盟 | 平安证券股份有限公司 | | | 彭天阳 | 光大证券股份有限公司 | | 时间 | 2021 年 12 月 16 | 日下午 | | 地点 | 一楼会议室 | | | 上市公 ...

证券代码：300412 证券简称：迦南科技 编号：20220722 | --- | --- | --- | --- | |-----------------------|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|----------------| | | | | | | | 特定对象调研 | □ 分析师会议 | | | | □ 媒体采访 | □ 业绩说明会 | | | 投资者关系 | □ 新闻发布会 | □ 路演活动 | | | 活动类别 | □ 现场参观 | | | | | □ 其他 | | | | 参与人员及 | 姓名 | 单位 | | | | 张楠 | 中泰证券股份有限公司 | 医药行业分析师 | | 单位 | 陈西铭 | 博时基金管理有限公司 | 基金经理 | | 时间 | 2022 年 7 月 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥493,831,145.02, representing a 14.33% increase compared to ¥431,933,108.57 in the same period last year[21]. - The net profit attributable to shareholders was ¥42,364,338.38, up 12.63% from ¥37,613,929.72 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥39,491,076.83, reflecting a 19.86% increase from ¥32,947,444.33 year-on-year[21]. - The net cash flow from operating activities was -¥39,524,231.35, a decline of 115.00% compared to -¥18,383,617.16 in the previous year[21]. - The total assets at the end of the reporting period were ¥2,489,395,163.35, an increase of 7.61% from ¥2,313,379,679.81 at the end of the previous year[21]. - The net assets attributable to shareholders increased by 2.19% to ¥1,156,679,410.31 from ¥1,131,882,953.25 at the end of the previous year[21]. - Basic earnings per share decreased by 40% to ¥0.09 from ¥0.15 in the previous year, primarily due to an increase in total share capital following the profit distribution[21]. - The weighted average return on net assets was 3.67%, down from 4.43% in the previous year[21]. - The gross profit margin for the pharmaceutical equipment sector was 34.96%, with a decrease of 5.49% compared to the previous year[51]. - The company reported a net profit of 15,954,405.98 CNY from Shanghai Kaixian, contributing significantly to overall performance[85]. - The intelligent warehousing subsidiary incurred a net loss of 7,432,249.46 CNY, indicating challenges in this segment[85]. - The pharmaceutical equipment subsidiary generated a revenue of 67,185,682.54 CNY, with a net profit of 11,422,343.79 CNY, showcasing strong performance[85]. Cash Flow and Investments - The net cash flow from operating activities decreased by 115.00% to -¥39,524,231.35, primarily due to increased payments related to business expansion[49]. - The net cash flow from financing activities increased by 156.80% to ¥37,452,119.44, mainly due to reduced bank financing repayments and dividends compared to the previous year[49]. - The total investment during the reporting period was ¥21,500,000, marking a 100% increase compared to the previous year[60]. - The company reported a fair value change gain of ¥467,768.71, contributing 0.83% to the total profit[54]. - The company has committed to several projects, including an intelligent logistics system with a total investment of ¥18,000 million, which is currently under construction[68]. - The pharmaceutical liquid system project has a total investment of ¥12,000 million, with cumulative investment reaching ¥11,986 million, achieving 99.89% of the expected progress[68]. - The upgrade and expansion of the pharmaceutical R&D service platform has a total investment of ¥5,000 million, with cumulative investment at ¥4,200 million, achieving 84.00% of the expected progress[68]. - The headquarters construction project has a total investment of ¥5,000 million, with cumulative investment fully utilized at 100%[68]. Market Position and Strategy - The company operates in the pharmaceutical equipment sector, providing integrated solutions for oral solid dosage intelligent factories, with a focus on high-end generic drugs and biopharmaceuticals[29]. - The company anticipates continued growth driven by the expansion of high-end generic drug production and the rapid development of the biopharmaceutical and logistics industries[30]. - The company has established a comprehensive pharmaceutical research and testing system through its subsidiary, Bixun Pharmaceutical, to support its service capabilities[30]. - The company has accumulated a large customer base primarily consisting of high-quality pharmaceutical enterprises, covering all regions in China except Taiwan and Macau, and extending to over 30 countries globally[38]. - The company has established a full product service research chain, integrating information consulting, pharmaceutical research, equipment support, and clinical trials, enhancing its comprehensive service capabilities[39]. - The company is positioned as a leading supplier of overall solutions for intelligent factories of oral solid dosage forms in China, with a focus on high-end generic drug solid dosage forms and biopharmaceutical innovation[40]. - The company is expected to benefit from favorable industry policies that support the pharmaceutical equipment manufacturing sector, enhancing its long-term growth prospects[38]. - The company has a strong market position due to its ability to provide high-value integrated equipment solutions and excellent service reputation, which are key drivers of its performance[38]. Research and Development - Research and development investment increased to ¥31,644,830.64, up 13.58% from the previous year, reflecting the company's commitment to new product and technology development[49]. - The company has established long-term stable relationships with major clients, including leading pharmaceutical companies, enhancing customer retention and market barriers[42]. - The company is actively exploring and establishing successful models of industry-university-research cooperation with several universities, enhancing its R&D capabilities[41]. - The company aims to enhance its service capabilities in drug information consulting, pharmaceutical research, pharmaceutical technology equipment, clean engineering support, and clinical trials through both organic and external growth strategies[39]. - The company has a structured profit distribution plan that prioritizes cash dividends when conditions are met[108]. Corporate Governance and Compliance - The company adheres to relevant laws and regulations, ensuring timely and accurate information disclosure to investors[104]. - The company has established a multi-tier governance structure, including a shareholders' meeting, board of directors, supervisory board, and management team[194]. - The company has implemented a comprehensive human resources management system, focusing on employee training and welfare[103]. - The company is currently fulfilling its commitments to shareholders without any delays[109]. - The company has not reported any changes in accounting policies or prior period error corrections during the reporting period[190]. Risks and Challenges - The company operates in the pharmaceutical equipment manufacturing industry, which is supported by national policies, but faces risks from potential changes in industry regulations and market demand[88]. - The domestic pharmaceutical equipment market is highly competitive, with significant pressure from both local and international manufacturers, particularly in the solid dosage equipment sector[89]. - There are risks associated with project funding and execution, as macroeconomic conditions and market dynamics may affect the expected outcomes of investment projects[91]. - The company faces integration risks as it expands through acquisitions, necessitating the alignment of governance structures and operational standards across subsidiaries[92]. Shareholder Information - The total number of shares increased from 292,798,022 to 497,756,637 after a capital reserve conversion and cash dividend distribution, with a cash dividend of CNY 0.6 per share totaling CNY 17.57 million[141]. - The largest shareholder, Canaan Technology Group, holds 19.68% of the shares, totaling 97,972,700 shares[147]. - The company has not conducted any repurchase agreements among the top 10 shareholders during the reporting period[148]. - The company reported a dilution effect on net assets per share due to the implementation of the profit distribution plan[143]. - The company plans to distribute at least 20% of its distributable profits as cash dividends if it is profitable and has positive retained earnings[108].

浙江迦南科技股份有限公司 2022 年第一季度报告全文 证券代码：300412 证券简称：迦南科技 公告编号：2022-038 浙江迦南科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 210,175,206.49 | 167,967,018.60 | 25.13% | | 归属于上市公司股东的净利润（元） | 18,094,190.28 | 10,757, ...

Dividend and Share Capital - The company plans to distribute a cash dividend of 0.60 CNY per 10 shares to all shareholders, based on a total of 292,798,022 shares[5]. - The company will increase its capital reserve by converting 7 shares for every 10 shares held by shareholders[5]. - The cash dividend represents 100% of the total distributable profit of RMB 227,642,668.88[154]. - The company plans to distribute profits in cash, stock, or a combination, prioritizing cash dividends when conditions allow, with a minimum cash distribution of 20% of distributable profits annually[171]. - In mature stages without major capital expenditures, the minimum cash dividend ratio should reach 80%, while it should be at least 40% if there are significant expenditures[172]. Financial Performance - The company's operating revenue for 2021 was ¥1,059,613,869.74, representing a 5.20% increase compared to ¥1,007,249,168.54 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥73,697,375.98, an increase of 8.53% from ¥67,905,492.79 in 2020[18]. - The total assets at the end of 2021 were ¥2,313,379,679.81, a 31.59% increase from ¥1,758,061,365.24 at the end of 2020[18]. - The net assets attributable to shareholders at the end of 2021 were ¥1,131,882,953.25, up 35.09% from ¥837,871,258.43 at the end of 2020[18]. - The company achieved total revenue of 1,059.61 million yuan, a year-on-year increase of 5.20%[59]. - The net profit attributable to shareholders was 73.70 million yuan, reflecting an 8.53% year-on-year growth[59]. Research and Development - The company holds a total of 695 authorized patents, including 38 invention patents and 2 U.S. patents[53]. - Research and development expenses increased by 34.73% to ¥66,976,218.78, driven by investments in new products and technologies[80]. - The company's R&D investment in 2021 amounted to ¥66,976,218.78, representing 6.32% of total revenue, an increase from 4.94% in 2020[83]. - The company plans to enhance product reliability and market competitiveness through ongoing R&D projects[81]. - The company is focusing on expanding its product lines in solid dosage forms, biopharmaceutical fluid systems, and smart logistics systems to increase market share[111]. Market and Industry Outlook - The global pharmaceutical market is expected to continue growing, driven by factors such as population growth and increasing health awareness, which will create more business opportunities for the company[29]. - The global pharmaceutical market is expected to grow at a CAGR of 3%-6% to reach $1.6 trillion by 2025, with oncology drug spending projected to exceed $260 billion by 2025[30]. - In China, the pharmaceutical market is anticipated to reach ¥1.729 trillion in 2021, with a CAGR of 5.4% from 2016 to 2021, and expected to grow at a CAGR of 7.2% to reach ¥2.287 trillion by 2025[32]. - The biopharmaceutical market in China is expected to grow at a CAGR of 17.6% from 2021 to 2025, reaching ¥811.6 billion by 2025, with a 24.57% market share in 2021[32]. Corporate Governance and Compliance - The company has established a governance structure that protects the rights of all shareholders, particularly minority shareholders[124]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[124]. - The company has maintained a transparent and compliant profit distribution policy, ensuring the protection of minority shareholders' rights[152]. - The company has not identified any significant internal control deficiencies during the reporting period[159]. - The company emphasizes compliance with legal regulations and shareholder rights in its operations and transactions[171]. Strategic Initiatives and Investments - The company is currently constructing a high-end intelligent pharmaceutical equipment production base, with cumulative investment reaching ¥192,877,675.00[94]. - The company plans to use the raised funds to accelerate capacity release and economic benefits through various projects, including the pharmaceutical liquid preparation system production center[62]. - The company aims to enhance its position as a supplier of intelligent factory solutions in the pharmaceutical equipment market and the smart logistics industry[110]. - The company is committed to fostering a close relationship with its stakeholders and ensuring effective communication regarding its operational strategies and financial performance[66]. Risks and Challenges - The company faces risks from policy changes in the pharmaceutical industry that could impact demand, necessitating timely adjustments in business strategies[115]. - The company is exposed to intensified market competition, particularly in the solid dosage equipment sector, where it competes against established foreign manufacturers[116]. - The company recognizes the risk of delayed customer project timelines affecting order fulfillment and revenue recognition, and will improve customer communication to mitigate this[118]. - The company has a potential goodwill impairment risk related to its acquisitions, which could negatively impact future financial performance if subsidiaries do not meet expected profitability[119]. Employee and Talent Management - The total number of employees at the end of the reporting period was 1,586, with 595 in the parent company and 991 in major subsidiaries[149]. - The company emphasizes a performance-based salary policy linked to economic efficiency and job responsibilities, aiming to attract and retain talent[150]. - The company emphasizes the importance of employee training, implementing targeted training programs to enhance professional skills and corporate culture[151]. - The company plans to strengthen talent development through improved performance evaluation, training systems, and incentive mechanisms to enhance operational efficiency[114].

Financial Performance - The company's revenue for Q3 2021 was CNY 320,423,944, representing a year-on-year increase of 19.72%[3] - Net profit attributable to shareholders decreased by 16.14% to CNY 20,068,363.16 in Q3 2021[3] - The basic earnings per share for Q3 2021 was CNY 0.08, down 11.11% compared to the same period last year[3] - Total operating revenue for Q3 2021 reached CNY 752.36 million, an increase of 24.5% compared to CNY 604.29 million in Q3 2020[24] - Net profit for Q3 2021 was CNY 70.71 million, representing a 30.6% increase from CNY 54.15 million in Q3 2020[25] - The basic earnings per share of CNY 0.22, compared to CNY 0.20 in the same quarter last year, reflecting a 10% increase[26] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 1,932,817,552.55, a 9.94% increase from the previous year[4] - The company's total assets increased to CNY 1.93 billion, up from CNY 1.76 billion year-over-year, reflecting a growth of 9.9%[22] - Total liabilities rose to CNY 1.02 billion, compared to CNY 871.13 million in the same period last year, marking an increase of 17.5%[22] - Long-term borrowings increased by 824.43% to CNY 8,244,270, primarily for financing the high-end intelligent medical equipment production base project[8] - The company’s long-term borrowings increased to CNY 92.44 million from CNY 10 million in the previous year, indicating a significant rise in financing activities[22] Cash Flow - Cash flow from operating activities showed a significant decline of 215.39%, resulting in a net outflow of CNY 18,160,569.37[9] - Cash flow from operating activities was CNY 616.17 million, up from CNY 530.10 million in the previous year, indicating a growth of 16.3%[27] - The net cash flow from operating activities was -¥18,160,569.37, a decrease from ¥15,738,938.47 in the previous year[28] - The total cash outflow from operating activities was ¥682,186,847.68, compared to ¥544,380,624.90 in the previous year[28] Research and Development - Research and development expenses increased by 50.75% year-on-year, amounting to CNY 4,740,000[8] - Research and development expenses for Q3 2021 were CNY 47.49 million, a significant increase of 50.7% from CNY 31.50 million in Q3 2020[24] Current Assets - As of September 30, 2021, the company's total current assets amounted to RMB 1,437,054,775.70, an increase from RMB 1,354,549,449.41 at the end of 2020, reflecting a growth of approximately 6.0%[20] - The company's cash and cash equivalents decreased to RMB 146,920,285.60 from RMB 253,042,131.82, representing a decline of about 42.0%[20] - Accounts receivable increased to RMB 372,995,888.06 from RMB 293,492,131.71, marking a rise of approximately 27.1%[20] - Inventory levels rose to RMB 695,837,806.13 from RMB 564,061,407.91, indicating an increase of around 23.4%[20] Equity and Shares - The total equity attributable to shareholders of the parent company was CNY 853.96 million, up from CNY 837.87 million year-over-year, an increase of 1.4%[22] - The company reported a total of 41,131,406 shares under lock-up agreements as of the end of the reporting period, with 6,600,000 shares newly added during the period[14] - The company is in the process of extending the validity period for issuing shares to specific targets, as approved in meetings held on September 29 and October 15, 2021[15] Legal Matters - The company faced a lawsuit regarding a rental contract dispute, with a claim amounting to RMB 244,200, which has since been resolved[18] Fixed and Intangible Assets - The company’s fixed assets were valued at RMB 206,147,605.00, showing a slight decrease from RMB 211,195,126.88 at the end of 2020[20] - The company’s intangible assets were reported at RMB 78,087,521.97, down from RMB 79,933,141.33, reflecting a decrease of approximately 2.3%[20] Audit Status - The company did not undergo an audit for the third quarter report[30]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥431,933,108.57, representing a 28.31% increase compared to ¥336,640,698.53 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2021 was ¥37,613,929.72, a 33.34% increase from ¥28,207,990.17 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥32,947,444.33, up 38.44% from ¥23,799,512.05 in the same period last year[21]. - The basic earnings per share for the first half of 2021 was ¥0.15, an increase of 36.36% compared to ¥0.11 in the previous year[21]. - The company's revenue for the reporting period was ¥431,933,108.57, representing a year-on-year increase of 28.31% due to expanded sales and business growth[46]. - The company reported a total revenue of 134,847,890.37 CNY from its subsidiary, Canaan Feiqi, with a net profit of 8,395,117.53 CNY[65]. - Canaan Technology's subsidiary, Shanghai Kaixian, generated a revenue of 62,280,073.93 CNY and a net profit of 11,224,140.50 CNY during the reporting period[65]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,862,891,686.07, a 5.96% increase from ¥1,758,061,365.24 at the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were ¥834,329,204.15, a slight decrease of 0.42% from ¥837,871,258.43 at the end of the previous year[21]. - The company's total liabilities were CNY 968,267,111.76, up from CNY 871,131,947.11, representing an increase of about 11.14%[144]. - The company's total assets as of June 30, 2021, amounted to CNY 1.15 billion, a slight increase from CNY 1.14 billion at the end of 2020[148]. - The company's total liabilities at the end of the first half of 2021 were CNY 1,000,000.00 million, reflecting a stable financial position[175]. Cash Flow - The net cash flow from operating activities was negative at -¥18,383,617.16, a significant decline of 180.28% compared to ¥22,898,297.94 in the same period last year[21]. - The net cash flow from investment activities was -¥110,759,964.42, a decrease of 110.27% compared to the previous year, mainly due to the use of idle funds for purchasing financial products[46]. - The net cash flow from financing activities was -¥65,933,742.30, a decrease of 223.82% compared to the previous year, attributed to reduced bank borrowings[46]. - The company's cash and cash equivalents decreased by 112.54% to -¥73,054,788.38, primarily due to reduced net cash flows from operating, investing, and financing activities[47]. - The cash and cash equivalents at the end of the period were CNY 156,250,443.68, down from CNY 198,794,569.56 at the end of the first half of 2020[160]. Research and Development - Research and development expenses increased by 45.24% to ¥27,861,588.37, reflecting the company's commitment to enhancing its R&D capabilities[46]. - The company has established a comprehensive pharmaceutical R&D and testing system through its subsidiary, providing services such as consistency evaluation for solid dosage forms and innovative drug technology development[30]. - The company aims to leverage the growth in the biopharmaceutical industry and the rapid development of intelligent logistics and drug R&D outsourcing to drive future performance[30]. - The company has accumulated 578 national authorized patents, including 36 invention patents, reflecting its strong intellectual property management and innovation capabilities[39]. Market Position and Strategy - The company operates in the pharmaceutical equipment sector, providing integrated solutions for solid dosage form intelligent factories, with a focus on high-end generic drugs and biopharmaceuticals[29]. - The company has a customized production model to meet the diverse needs of pharmaceutical enterprises, enhancing its service capabilities[30]. - The company has a robust customer base, serving well-known pharmaceutical enterprises globally, including Sanofi, Novartis, and Pfizer, which enhances customer retention and market barriers[39]. - The company is positioned in a policy-supported industry, benefiting from various government initiatives aimed at enhancing the pharmaceutical equipment manufacturing sector[35]. - The company plans to adapt its business strategies in response to potential regulatory changes in the pharmaceutical industry, aiming to diversify its product offerings and extend its industrial chain[67]. Risks and Challenges - The company faces risks related to management and human resources as it expands, necessitating optimization of its management system and the establishment of a scientific compensation system[70]. - Delays in customer engineering progress can extend the sales cycle for orders, potentially impacting revenue recognition[71]. - The company is undertaking mergers and acquisitions, which increases the risk of integration challenges across subsidiaries in terms of business systems and corporate culture[71]. - There is a risk of goodwill impairment related to acquisitions made in previous years if subsidiaries do not meet performance expectations due to increased market competition[71]. Governance and Compliance - The company has established a multi-tier governance structure, including a board of directors and various specialized committees[181]. - The company adheres to the Chinese accounting standards and has no significant doubts regarding its ability to continue as a going concern[186][187]. - The semi-annual financial report has not been audited[91]. - The company has not engaged in any significant related party transactions during the reporting period[101]. Social Responsibility - The company actively fulfills its social responsibilities and provides equal development opportunities for employees[84]. - The company has established a comprehensive performance evaluation system for employees[84].